Cancer treatment and research communications最新文献

{"title":"A randomized controlled trial: Effects of compression therapy combined with exercise on chemotherapy-induced peripheral neuropathy in patients with breast cancer","authors":"Yu Xiaoqian ,&nbsp;Hu Jiwei ,&nbsp;Zhou Lizhi ,&nbsp;Guo Baojia ,&nbsp;Guo Luyan ,&nbsp;Xu Huiqian ,&nbsp;Li Hong ,&nbsp;Fan Yijing","doi":"10.1016/j.ctarc.2025.100871","DOIUrl":"10.1016/j.ctarc.2025.100871","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the effects of compression therapy combined with exercise for cancer patients (EXCAP) in patients with peripheral neuropathy caused by breast cancer chemotherapy.</div></div><div><h3>Methods</h3><div>Overall, 108 patients with peripheral neuropathy after chemotherapy for breast cancer were randomly divided into the control group (routine nursing), experimental group 1 (compression therapy), and experimental group 2 (compression therapy and EXCAP). The National Institute of Cancer Drug Toxicity Rating Scale and the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool were assessed and compared between groups.</div></div><div><h3>Results</h3><div>The incidence of grade 0 peripheral neuropathy in both experimental groups was higher than that in controls (<em>P</em> &lt; 0.001), and the incidence in group 2 was higher than that in group 1 (<em>P</em> &lt; 0.001). The incidence of grade 2 disease in both experimental groups was lower than that in controls (<em>P</em> &lt; 0.001). The rate of symptoms in both experimental groups after the intervention were lower than that in the control group (<em>P</em> &lt; 0.001), and those in experimental group 2 were lower than those in experimental group 1 (<em>P</em> &lt; 0.001). Scores regarding activities of daily living in the experimental groups were lower than those of the control group (<em>P</em> &lt; 0.001), and lower in group 2 than in group 1 (<em>P</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Compression therapy and EXCAP can effectively reduce the incidence of chemotherapy-induced peripheral neuropathy in patients undergoing breast cancer chemotherapy. They can both positively impact patients' daily lives and symptom experiences; however, they are more effective when combined.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100871"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy","authors":"Sajjad Ahmadpour ,&nbsp;Mohammad Amin Habibi ,&nbsp;Farzaneh Sadat Ghazi ,&nbsp;Mikaeil Molazadeh ,&nbsp;Mohammad Reza Pashaie ,&nbsp;Yousef Mohammadpour","doi":"10.1016/j.ctarc.2024.100823","DOIUrl":"10.1016/j.ctarc.2024.100823","url":null,"abstract":"<div><p>Tumors can produce bioactive substances called tumor-derived supernatants (TDS) that modify the immune response in the host body. This can result in immunosuppressive effects that promote the growth and spread of cancer. During tumorigenesis, the exudation of these substances can disrupt the function of immune sentinels in the host and reinforce the support for cancer cell growth. Tumor cells produce cytokines, growth factors, and proteins, which contribute to the progression of the tumor and the formation of premetastatic niches. By understanding how cancer cells influence the host immune system through the secretion of these factors, we can gain new insights into cancer diagnosis and therapy.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100823"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000352/pdfft?md5=50a6996ac4bc66271d4187b169d09594&pid=1-s2.0-S2468294224000352-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141278925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the genetic landscape of hereditary melanoma: From susceptibility to surveillance","authors":"Chenming Zheng,&nbsp;Kavita Y. Sarin","doi":"10.1016/j.ctarc.2024.100837","DOIUrl":"10.1016/j.ctarc.2024.100837","url":null,"abstract":"<div><p>The multifactorial etiology underlying melanoma development involves an array of genetic, phenotypic, and environmental factors. Genetic predisposition for melanoma is further influenced by the complex interplay between high-, medium-, and low-penetrance genes, each contributing to varying degrees of susceptibility. Within this network, high-penetrance genes, including <em>CDKN2A, CDK4, BAP1</em>, and <em>POT1,</em> are linked to a pronounced risk for disease, whereas medium- and low-penetrance genes, such as <em>MC1R, MITF</em>, and others, contribute only moderately to melanoma risk. Notably, these genetic factors not only heighten the risk of melanoma but may also increase susceptibility towards internal malignancies, such as pancreatic cancer, renal cell cancer, or neural tumors. Genetic testing and counseling hold paramount importance in the clinical context of suspected hereditary melanoma, facilitating risk assessment, personalized surveillance strategies, and informed decision-making. As our understanding of the genomic landscape deepens, this review paper aims to comprehensively summarize the genetic underpinnings of hereditary melanoma, as well as current screening and management strategies for the disease.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100837"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000492/pdfft?md5=9f10c8ce18e2ed33ecd14aa1c68588fa&pid=1-s2.0-S2468294224000492-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment","authors":"Saki Tanaka ,&nbsp;Motohiro Tamiya ,&nbsp;Satoshi Nishiuma ,&nbsp;Sayaka Nakamura ,&nbsp;Keisuke Nozaki ,&nbsp;Naoko Watanabe ,&nbsp;Chisae Itoh ,&nbsp;Yukio Kadokawa ,&nbsp;Kenji Takeda ,&nbsp;Kozo Takahashi ,&nbsp;Akito Miyazaki ,&nbsp;Takahisa Kawamura ,&nbsp;Kei Kunimasa ,&nbsp;Takako Inoue ,&nbsp;Kazumi Nishino ,&nbsp;Mari Takagi","doi":"10.1016/j.ctarc.2024.100836","DOIUrl":"10.1016/j.ctarc.2024.100836","url":null,"abstract":"<div><h3>Background</h3><p>The most recommended treatment for stage IV EGFR-positive lung cancer is osimertinib monotherapy. The dosage of osimertinib is fixed at 80 mg/day regardless of body surface area (BSA), however some patients withdraw or reduce the dosage due to adverse events (AEs).</p></div><div><h3>Methods</h3><p>We performed a retrospective cohort study of 98 patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who received 80 mg osimertinib as the initial treatment. We investigated the impact of BSA on efficacy and safety of osimertinib.</p></div><div><h3>Results</h3><p>The cut-off value of BSA was estimated using the receiver operating characteristics curve, and was determined to be 1.5 m². There were 44 patients in the BSA &lt; 1.5 group and 54 patients in the BSA ≥ 1.5 group. There was no significant difference in the incidence of AEs (hematologic toxicity of ≥grade 3 or higher, and non-hematologic toxicity of ≥grade 3) between the two groups. However, the incidence of dose reduction due to AEs was significantly higher in the BSA &lt; 1.5 group compared with the BSA ≥ 1.5 group (16 patients vs 5 patients, <em>p</em> = 0.003). The main reasons were fatigue, anorexia, diarrhea, and liver disfunction. Median progression-free survival (PFS) was not significantly different (16.9 months in the BSA &lt; 1.5 group vs 18.1 months in the BSA ≥ 1.5 group, <em>p</em> = 0.869).</p></div><div><h3>Conclusion</h3><p>Differences in BSA affected the optimal dose of osimertinib. However, the PFS with osimertinib treatment was not affected by BSA. Therefore, when using osimertinib as an initial treatment for patients with EGFR-mutant NSCLC, dose reduction to control AEs should be considered, especially in the BSA&lt;1.5 group.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100836"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000480/pdfft?md5=9618c1dc15ff3738502bc6dd4ff016f7&pid=1-s2.0-S2468294224000480-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of neoadjuvant chemotherapy in pregnancy with cervical cancer (IB3)","authors":"Xiaohua Li ,&nbsp;Yu Zhang ,&nbsp;Haiying Wu ,&nbsp;Shaoqiong Li ,&nbsp;Shuxian Ge ,&nbsp;Jian Gao","doi":"10.1016/j.ctarc.2023.100749","DOIUrl":"10.1016/j.ctarc.2023.100749","url":null,"abstract":"<div><p>Compared with the early symptoms of non-pregnancy, the early pregnancy with cervical cancer is often confused with threatened abortion, so it is difficult to diagnose and delay the time of treatment. At present, compared with cervical cancer, there is no clear and standard treatment for cervical cancer in pregnancy. At present, the diagnosis and treatment plan is mainly made according to the pathological examination, staging, fetal development (whether there is abnormality on ultrasound and whether the chromosome karyotype is normal or not) and the pregnant women and their family members’ pregnancy wishes. A case of pregnancy complicated with cervical cancer who was terminated by planned cesarean section after neoadjuvant chemotherapy (NACT) with irregular vaginal bleeding as the first symptom was analyzed retrospectively.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"38 ","pages":"Article 100749"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294223000710/pdfft?md5=f9b40e7d3b275a37f39006f987756fb8&pid=1-s2.0-S2468294223000710-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48065102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Bleomycin Deficit on Survival in Hodgkin's Lymphoma Patients: A Retrospective Study","authors":"Luiz Ricardo Soldi ,&nbsp;Diogo Henrique Rabelo ,&nbsp;Paulo Henrique Rosa da Silva ,&nbsp;Victor Luigi Costa Silva ,&nbsp;Marcelo José Barbosa Silva","doi":"10.1016/j.ctarc.2024.100790","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100790","url":null,"abstract":"<div><h3>Purpose</h3><p>Hodgkin's lymphoma is currently treated with a chemotherapy protocol consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine. Due to Brazil facing a bleomycin shortage in 2017, and this drug's high toxicity, this retrospective study evaluates the effect that the absence of bleomycin had on treatment response and overall survival of Hodgkin's lymphoma patients.</p></div><div><h3>Methods</h3><p>The medical records of 126 HL patients treated between 2007 and 2021 were reviewed and their data collected, followed by grouping into ABVD and AVD groups according to bleomycin use. Data concerning the patient's characteristics, cancer type, and treatment plan were analyzed with proportion tests, Kaplan-Meier curves. univariate Cox regression, and χ² tests.</p></div><div><h3>Results</h3><p>No discernible differences were found in this study between the overall survival and recurrence rate of patients treated with bleomycin compared to those without. Additionally, there was an increased risk of death in each subsequent cycle of chemotherapy of the complete ABVD protocol, demonstrating a risk of toxicity. Among the variables analyzed, hypertension and the presence of B symptoms were also associated with an increased risk of death, while the use of radiotherapy significantly improved survival.</p></div><div><h3>Conclusion</h3><p>The results of this study suggest that bleomycin did not impact the outcome of Hodgkin's lymphoma treatment. Moreover, the increased risk of death associated with its toxicity during each cycle of treatment raises concerns about its role as an essential component of the gold standard for Hodgkin's lymphoma treatment. Therefore, further research and consideration are needed to reassess the use of bleomycin in Hodgkin's lymphoma treatment protocols.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"38 ","pages":"Article 100790"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000029/pdfft?md5=83cf927e29ef9f9a348333ad2ed4c115&pid=1-s2.0-S2468294224000029-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139494074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rectal cancer survival and prognostic factors in Iranian population: A retrospective cohort study","authors":"Seyed Kazem Mirinezhad ,&nbsp;Mostafa Akbarzadeh-Khiavi ,&nbsp;Farshad Seyednejad ,&nbsp;Mohammad Hossein Somi","doi":"10.1016/j.ctarc.2024.100810","DOIUrl":"10.1016/j.ctarc.2024.100810","url":null,"abstract":"<div><h3>Background</h3><p>Rectal cancer (RC) poses a significant global health challenge, causing substantial morbidity and mortality. This study aims to investigate the survival rates of RC patients and identify the factors that influence their survival. The study considers demographic characteristics, tumor features, and treatment received as the factors under consideration.</p></div><div><h3>Methods</h3><p>A retrospective analysis was conducted on the medical records of 593 RC patients. Data were collected through a comprehensive review of medical records and conducting telephone interviews. Survival rates were estimated using the life table method, and subgroup comparisons were performed using the log-rank test. Cox regression analysis was utilized to assess the independent associations between RC survival time and various covariates.</p></div><div><h3>Results</h3><p>The study cohort comprised 593 RC patients, with a predominantly male representation. The mean age at diagnosis was 58.18 years, and the majority of patients (78.6 %) underwent surgical interventions. The median age at symptom onset and diagnosis were 58 and 59 years, respectively. Survival rates at 1st, 3rd, 5th, and 10th years were estimated to be 85 %, 59 %, 47 %, and 36 %, respectively. Statistical analysis revealed several significant prognostic factors, including age, education, symptoms, and cancer stage. In the multivariate Cox proportional-hazards analysis, advanced regional stage (HR = 1.54, 95 % CI, 1.13–2.08), presence of metastasis (HR = 3.73, 95 % CI, 2.49–5.58), and age over 70 (HR = 1.65) were associated with a higher risk of mortality.</p></div><div><h3>Conclusion</h3><p>Given the alarming prognosis of RC observed in the study area and the significant delay between symptom onset and diagnosis, it is crucial to address this issue and potentially improve the survival rates of RC patients.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100810"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000224/pdfft?md5=f3cd7f224a762464d244f0a233e484b3&pid=1-s2.0-S2468294224000224-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140402897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes of physicians and patients toward immediate and intraoperative chemotherapy treatment in colon cancer","authors":"Mehraneh D. Jafari ,&nbsp;Andrea Mesiti ,&nbsp;Julianna Brouwer ,&nbsp;Chelsea McKinney ,&nbsp;Lari B. Wenzel ,&nbsp;Alessio Pigazzi ,&nbsp;Jason A. Zell","doi":"10.1016/j.ctarc.2024.100798","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100798","url":null,"abstract":"<div><h3>Introduction</h3><p>We have shown in a Phase I trial that immediate adjuvant chemotherapy (IAC) during surgical resection and immediately postoperative is safe and feasible in patients with colon cancer (CC). IAC avoids delays in adjuvant treatment and has the potential to improve survival and quality of life. We aim to determine patients and providers attitudes toward this novel multidisciplinary treatment approach.</p></div><div><h3>Methods</h3><p>Two web-based surveys were administered to newly diagnosed CC patients, survivors, surgeons and oncologists. Surveys assessed treatment preferences and perceived barriers to IAC. Chi-square tests were conducted to compare differences between patients’ and providers’ responses.</p></div><div><h3>Results</h3><p>Responses were collected from 35 patients and 40 providers. Patients were more willing to: (1) proceed with IAC to finish treatment earlier thus possibly improving quality of life (<em>p</em> = 0.001); (2) proceed with IAC despite potential side effects (<em>p</em> &lt; 0.001); and (3) proceed with a dose of intraoperative chemotherapy even if on final pathology, may not have been needed (<em>p</em> = 0.002). Patients were more likely to indicate no barriers to collaborative care (<em>p</em> = 0.001) while providers were more likely to cite that it is time consuming, thus a barrier to participation (<em>p</em> = 0.001), has scheduling challenges (<em>p</em> = 0.001), and physicians are not available to participate (<em>p</em> = 0.003).</p></div><div><h3>Conclusions</h3><p>We observed a discordance between what providers and patients value in perioperative and adjuvant CC treatment. Patients are willing to accept IAC despite potential side effects and without survival benefit, highlighting the importance of understanding patient preference.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100798"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000108/pdfft?md5=8ca70afb2272b954ac368cf708081f3c&pid=1-s2.0-S2468294224000108-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140030977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer","authors":"Maria Ignez Freitas Melro Braghiroli ,&nbsp;Daniel Santos Rocha Sobral Filho ,&nbsp;Juliana Goes Martins Fagundes ,&nbsp;Elizabeth Zambrano Mendoza ,&nbsp;Maria Fernanda Batistuzzo Vicentini Neffa ,&nbsp;Karla Souza Campos ,&nbsp;Leonardo Gomes da Fonseca ,&nbsp;Renata Colombo Bonadio ,&nbsp;Aley Talans ,&nbsp;Oddone Freitas Melro Braghiroli ,&nbsp;Maria Cecília Mathias-Machado ,&nbsp;Jorge Sabbaga ,&nbsp;Camila Motta Venchiarutti Moniz ,&nbsp;Paulo Marcelo Gehm Hoff","doi":"10.1016/j.ctarc.2025.100867","DOIUrl":"10.1016/j.ctarc.2025.100867","url":null,"abstract":"<div><h3>Purpose</h3><div>There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment for metastatic colorectal cancer.</div></div><div><h3>Methods</h3><div>This is a retrospective cohort of metastatic colorectal cancer patients who progressed to irinotecan monotherapy and were exposed to an anti-EGFR antibody as a third line of treatment. This study was conducted at a single cancer center in Brazil. The primary outcome was overall survival. The secondary outcomes were objective response rate, stratified by primary tumor sidedness, progression-free survival, and toxicity.</div></div><div><h3>Results</h3><div>This analysis included 412 patients who had progressed on irinotecan and were KRAS wild-type. One hundred eighty-two received Irinotecan plus Cetuximab (I + C group) and 230 Irinotecan plus Panitumumab (<em>I</em> + <em>P</em> group). There was no significant difference in median overall survival between treatment groups (9.1 months [I + C] vs 10.1 months [<em>I</em> + <em>P</em>]; <em>p</em> = 0.76). There was also no difference in progression-free survival (3.63 months [I + C] vs 3.73 months [<em>I</em> + <em>P</em>]; <em>p</em> = 0.19) and objective response rate (23.0 % [I + C] vs 22.3 % [<em>I</em> + <em>P</em>]; <em>p</em> = 0.97). Patients with right-sided tumors had worse overall survival than left-sided (6.2 months vs 10.1 months; <em>p</em> = 0.003) but presented a better objective response rate with panitumumab (8.3 % [<em>I</em> + <em>P</em>] vs 3.3 % [I + C]). There were more infusion reactions with cetuximab.</div></div><div><h3>Conclusions</h3><div>Panitumumab and cetuximab have similar activity when combined with irinotecan as treatment for patients with disease progression with an irinotecan regimen, potentially rescuing the irinotecan activity.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100867"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations","authors":"Jason C.S. Ho,&nbsp;K.M. Cheung","doi":"10.1016/j.ctarc.2025.100863","DOIUrl":"10.1016/j.ctarc.2025.100863","url":null,"abstract":"<div><div>Unresectable stage III non-small cell lung cancer (NSCLC) carries a poor prognosis. The PACIFIC trial established consolidation durvalumab after chemoradiation as a standard treatment; however, its efficacy in patients with driver mutations remains uncertain. This retrospective cohort study analyzed data from three oncology centers in Hong Kong, covering the period from January 2019 to December 2022. Among the 123 patients who underwent definitive chemoradiation, 33 had common driver mutations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and RET fusions. The addition of durvalumab did not improve real-world recurrence-free survival (rwRFS) in patients with these mutations (hazard ratio [HR] 0.852, 95 % confidence interval [CI] 0.394 – 1.843, <em>p</em>= 0.683). In contrast, rwRFS significantly improved for patients without common mutations (HR 0.342, 95 % CI 0.203 – 0.577, <em>p</em>&lt; 0.001). These findings suggest that consolidation durvalumab may not be beneficial for patients with common driver mutations, underscoring the need for personalized treatment strategies in this population.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100863"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}